ReviewMolecular biology reports2026
Context-dependent NRF2 signaling in cancer: mechanisms and precision modulation.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear factor erythroid 2-related factor 2 (NRF2) is a central transcription factor in the cellular antioxidant stress response, whose activity exhibits marked context-dependence. Under normal physiological conditions and in precancerous lesions, timely and moderate activation of the NRF2 pathway establishes a multi-layered, synergistic cellular defense network. Through mechanisms including efficient detoxification of exogenous carcinogens, clearance of excess reactive oxygen species (ROS), suppression of chronic inflammation, maintenance of genomic stability, regulation of autophagic homeostasis, and promotion of immune surveillance to eliminate precancerous cells, NRF2 exerts potent chemopreventive effects, thereby preventing malignant transformation. In established malignancies, however, constitutive activation of the NRF2 pathway—driven by mutations in KEAP1/NRF2 or persistent oncogenic signaling—fundamentally reverses its role. Under these conditions, NRF2 becomes a central hub that promotes tumor progression and therapy resistance by remodeling redox homeostasis to sustain low ROS levels favorable for proliferation, reprogramming metabolism to support biosynthetic demands, upregulating multidrug resistance-associated proteins, and shaping an immunosuppressive tumor microenvironment. This review examines the molecular basis of the dual roles of NRF2 at different stages of carcinogenesis and summarizes the distinct biological effects of natural and synthetic modulators of this pathway.
Indexed as
Identifiers
42033630What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.